{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T13:51:49Z","timestamp":1761486709925},"reference-count":85,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2003,12,12]],"date-time":"2003-12-12T00:00:00Z","timestamp":1071187200000},"content-version":"vor","delay-in-days":1928,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[1998,9]]},"abstract":"<jats:p>Patients with haemophilia often exhibit a variety of disturbances in immune function. Although infections with HIV, hepatitis and other viruses no doubt contribute to these abnormalities, chronic exposure to extraneous proteins in clotting factor concentrates (CFCs) may also play a role. Numerous <jats:italic>in vitro <\/jats:italic>and <jats:italic>ex vivo<\/jats:italic> studies show that protein contaminants \u2013 such as immunoglobulins, fibrinogen and fibronectin \u2013 can depress various immune function indicators. Generally, such studies show that intermediate\u2010purity CFCs are more inhibitory than very high\u2010purity (e.g. monoclonal\u2010purified) CFCs. In many, but not all, studies, the degree of immunosuppression correlates with the amount of intermediate\u2010purity CFC administered over time. \u2003Among various indicators of immune function, CD4+ lymphocyte number is a marker for the progression of HIV infection, and maintenance of CD4+ number is associated with delayed progression. A number of studies suggest that, compared with intermediate\u2010purity CFCs, use of very high\u2010purity CFCs is associated with longer preservation of this class of lymphocytes. However, it remains to be seen whether this translates to improved long\u2010term clinical outcomes. \u2003Further research is needed on the impact of CFCs on the immune system. For the time being, however, evidence to date favours the use of very high\u2010purity products because they appear to preserve immune function and reduce the risk of infection with hepatitis and other viruses.<\/jats:p>","DOI":"10.1046\/j.1365-2516.1998.00172.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T22:55:20Z","timestamp":1047423320000},"page":"704-713","source":"Crossref","is-referenced-by-count":17,"title":["Clotting factor concentrates and immune function in haemophilic patients"],"prefix":"10.1111","volume":"4","author":[{"given":"K.","family":"Hoots","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Canty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2003,12,12]]},"reference":[{"key":"e_1_2_7_2_2","first-page":"10","article-title":"Understanding the hemophilias: factor VIII deficiency (hemophilia A)","volume":"4","author":"Davignon GF","year":"1991","journal-title":"Hemalog"},{"key":"e_1_2_7_3_2","unstructured":"HandinRI.Disorders of coagulation and thrombosis. In: Wilson JD Braunwald E Isselbacher KJ Petersdorf RG Martin JB Fauci AS Root RK eds.Harrison\u2019s Principles of Internal Medicine 12th edn. New York: McGraw Hill Inc.1991: 1505\u201311."},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198910263211702"},{"key":"e_1_2_7_5_2","unstructured":"BrettlerDB.A multicentre study to determine the hepatitis safety of Monoclate. Presented at:Replacement Therapy in Haemophilia \u2013 Problems and Solutions. Nov 3\u201341988; Lisbon Portugal."},{"key":"e_1_2_7_6_2","doi-asserted-by":"crossref","unstructured":"GompertsED De BiasiR De VrekerR.The impact of clotting factor concentrates on the immune system in individuals with hemophilia.Trans Med Revs1992; VI:44\u201354.","DOI":"10.1016\/S0887-7963(92)70155-2"},{"key":"e_1_2_7_7_2","unstructured":"NHF\/MASAC (National Hemophilia Foundation\/Medical Scientific Advisory Council). Recommendations concerning HIV infection hepatitis and other transmissable agents in the treatment of hemophilia.Hemophilia Information Exchange: Medical Bulletinno.226(Revised March 1995)."},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/0090-1229(86)90249-7"},{"key":"e_1_2_7_9_2","first-page":"318","article-title":"Immunoresponsiveness in haemophilia: lymphocyte and phagocyte mediated functions","volume":"5","author":"Antonaci S","year":"1988","journal-title":"Diagn Clin Immunol"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1089\/jir.1988.8.89"},{"key":"e_1_2_7_11_2","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1182\/blood.V67.1.164.164","article-title":"Natural killer cell activity from hemophiliacs exhibits differential responses to various forms of interferon","volume":"67","author":"Matheson DS","year":"1986","journal-title":"Blood"},{"key":"e_1_2_7_12_2","first-page":"491","article-title":"Abnormal B cell function in haemophiliacs and their relationship with factor concentrate administration","volume":"59","author":"Brieva JA","year":"1985","journal-title":"Clin Exp Immunol"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01703246"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/0165-2478(85)90112-9"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.293.6553.978"},{"key":"e_1_2_7_16_2","first-page":"38","article-title":"c purified from plasma via monoclonal antibodies: Human studies","volume":"25","author":"Levine PH","year":"1988","journal-title":"Semin Hematol"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(86)90545-0"},{"key":"e_1_2_7_18_2","doi-asserted-by":"crossref","unstructured":"LudlamCA CarrR VeitchE SteelCM.Disordered immune regulation in haemophiliacs not exposed to commercial factor VIII.Lancet1983; I: 1226.","DOI":"10.1016\/S0140-6736(83)92511-4"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.287.6399.1091"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(84)91931-7"},{"key":"e_1_2_7_21_2","first-page":"30","article-title":"Humoral and cellular immune abnormalities in adult hemophiliacs followed over a two\u2010year period","volume":"5","author":"Freedman I","year":"1987","journal-title":"Diagn Clin Immunol"},{"key":"e_1_2_7_22_2","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1182\/blood.V70.3.786.786","article-title":"1986 update of HIV seroprevalence, AIDS incidence and immunologic correlates of HIV infection in patients with haemophilia A and B","volume":"70","author":"Ragni MV","year":"1987","journal-title":"Blood"},{"key":"e_1_2_7_23_2","first-page":"1095","article-title":"Relationship of CD4 lymphocyte counts to survival in a cohort of hemophiliacs infected with HIV","volume":"10","author":"Ehmann WC","year":"1994","journal-title":"JAIDS"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.304.6821.212"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198707303170505"},{"key":"e_1_2_7_26_2","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1182\/blood.V74.1.298.298","article-title":"Helper and suppressor T\u2010cell function in HIV\u2010infected hemophilia patients","volume":"74","author":"Weimer R","year":"1989","journal-title":"Blood"},{"key":"e_1_2_7_27_2","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1182\/blood.V69.5.1388.1388","article-title":"Defect in B cell function in HTLV III\/LAV positive hemophilia patients","volume":"69","author":"Sjamsoedin\u2010Visser LJM","year":"1987","journal-title":"Blood"},{"key":"e_1_2_7_28_2","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1182\/blood.V72.5.1474.1474","article-title":"Defective T suppressor\u2010inducer cell function in human immune deficiency virus\u2010seropositive hemophilia patients","volume":"72","author":"Sjamsoedin\u2010Visser LJM","year":"1988","journal-title":"Blood"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/0165-2478(90)90050-Z"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.1981.tb00663.x"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1159\/000419337"},{"key":"e_1_2_7_32_2","article-title":"Interactions between HIV1, hepatitis delta, and HBV infections","volume":"12","author":"Housset C","year":"1990","journal-title":"Hepatol"},{"key":"e_1_2_7_33_2","doi-asserted-by":"crossref","unstructured":"WebsterA LeeCA CookDG et al.Cytomegalovirus infection and progression towards AIDS in haemophiliacs with human immunodeficiency virus infection.Lancet1989; II:63\u20136.","DOI":"10.1016\/S0140-6736(89)90312-7"},{"key":"e_1_2_7_34_2","first-page":"602","article-title":"Natural history of hepatitis C virus infection in multitransfused hemophiliacs: effect of coinfection with human immunodeficiency virus","volume":"6","author":"Eyster ME","year":"1993","journal-title":"J Acquir Immune Defic Syndr"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1994.tb05038.x"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1995.tb05269.x"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1995.tb05268.x"},{"key":"e_1_2_7_38_2","first-page":"3244","article-title":"Isolation and characterization of an immunosuppressive acidic protein from ascitic fluids of cancer patients","volume":"41","author":"Tamara K","year":"1981","journal-title":"Cancer Res"},{"key":"e_1_2_7_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(86)90782-9"},{"key":"e_1_2_7_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(84)90313-9"},{"key":"e_1_2_7_41_2","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1182\/blood.V69.4.1153.1153","article-title":"A component of factor VIII preparations which can be separated from factor VIII activity down modulates human monocyte functions","volume":"69","author":"Eibl MM","year":"1987","journal-title":"Blood"},{"key":"e_1_2_7_42_2","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1182\/blood.V71.6.1662.1662","article-title":"Comparable modulation of human monocyte functions by commercial factor VIII concentrates of varying purity","volume":"71","author":"Mannhalter JW","year":"1988","journal-title":"Blood"},{"key":"e_1_2_7_43_2","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1182\/blood.V75.3.810b.810b","article-title":"Modulation of human monocyte functions by factor VIII \u2013 anti factor VIII complexes present in an affinity\u2010purified factor VIII product","volume":"75","author":"Mannhalter JW","year":"1990","journal-title":"Blood"},{"key":"e_1_2_7_44_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1978.18579036390.x"},{"key":"e_1_2_7_45_2","first-page":"3","article-title":"Effects of allogens in blood products on immunity","volume":"25","author":"Ludlam CA","year":"1988","journal-title":"Semin Hematol"},{"key":"e_1_2_7_46_2","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1182\/blood.V59.4.681.681","article-title":"Fibronectin mediates attachment of Staphylococcus aureus to human neutrophils","volume":"59","author":"Proctor RA","year":"1982","journal-title":"Blood"},{"key":"e_1_2_7_47_2","first-page":"729","article-title":"Fibronectin concentration is decreased in plasma of severely ill patients with disseminated intravascular coagulation","volume":"91","author":"Mosher DF","year":"1978","journal-title":"J Lab Clin Med"},{"key":"e_1_2_7_48_2","unstructured":"PasiKJ HillFGH.Correlation between increasing product purity and reduced inhibition of monocyte phagocytic function. In: Mannucci PM ed.Replacement Therapy in Haemophilia \u2013 Problems and Solutions. Lisbon: Alden Press 1988: 116\u20139."},{"key":"e_1_2_7_49_2","doi-asserted-by":"publisher","DOI":"10.1159\/000205685"},{"key":"e_1_2_7_50_2","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1182\/blood.V82.7.2258b.2258b","article-title":"Increased levels of serum intercellular adhesion molecule 1 in hemophiliacs irrespective of human immunodeficiency virus type 1 infection","volume":"82","author":"Matsuda J","year":"1993","journal-title":"Blood"},{"key":"e_1_2_7_51_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1650257"},{"key":"e_1_2_7_52_2","first-page":"62","article-title":"Influence of factor VIII, factor IX and immunoglobulin preparations of proliferative responses of mitogen\u2010activated lymphocytes","volume":"15","author":"Gl\u00f6ckel U","year":"1987","journal-title":"Immun Infect"},{"key":"e_1_2_7_53_2","article-title":"In vitro immune parameters of Monclate, a monoclonal antibody purified human plasma factor VIII.c therapeutic preparation","volume":"58","author":"Schreiber AB","year":"1987","journal-title":"Thromb Haemost"},{"key":"e_1_2_7_54_2","article-title":"The variable effect of diverse clotting factor concentrates on lymphocyte function in vitro","volume":"62","author":"Hay CRM","year":"1989","journal-title":"Thromb Haemost"},{"key":"e_1_2_7_55_2","first-page":"471","article-title":"Antihemophilic factor (factor VIII) preparations inhibit lymphocyte proliferation and production of interleukin\u20102","volume":"107","author":"Lederman MM","year":"1986","journal-title":"J Lab Clin Med"},{"key":"e_1_2_7_56_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1989.tb04296.x"},{"key":"e_1_2_7_57_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1990.tb07838.x"},{"key":"e_1_2_7_58_2","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.38.10.1163"},{"key":"e_1_2_7_59_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1992.tb06470.x"},{"key":"e_1_2_7_60_2","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1182\/blood.V84.6.2021.2021","article-title":"Identification of transforming growth factor\u2010beta as a contaminant in factor VIII concentrates: a possible link with immunosuppressive effects in hemophiliacs","volume":"84","author":"Wadhwa M","year":"1994","journal-title":"Blood"},{"key":"e_1_2_7_61_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1992.tb04599.x"},{"key":"e_1_2_7_62_2","unstructured":"BerntorpE.Lectin\u2010induced lymphocyte transformation after infusion of factor VIII concentrates. In: Mannucci PM ed.Replacement Therapy in Haemophilia \u2013 Problems and Solutions. Lisbon: Alden Press 1988: 129."},{"key":"e_1_2_7_63_2","first-page":"27","article-title":"The preclinical characterization of Monoclate factor VIII.c antihaemophilic factor (human)","volume":"25","author":"Schreiber A","year":"1988","journal-title":"Semin Haematol"},{"key":"e_1_2_7_64_2","article-title":"Commercial factor VIII concentrates alter human monocyte functions in vitro","volume":"25","author":"Janco L","year":"1989","journal-title":"Pediatr Res"},{"key":"e_1_2_7_65_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1992.tb08147.x"},{"key":"e_1_2_7_66_2","article-title":"Multicenter study on the influence of long\u2010term continous use of ultrapurified factor VIII preparation on the immunological status of HIV infected and non\u2010infected hemophilia A patients","volume":"124","author":"Fukutake K","year":"1990","journal-title":"XIXth International Congress of the World Federation of Hemophilia"},{"key":"e_1_2_7_67_2","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1182\/blood.V83.7.1958.1958","article-title":"Immune status of human immunodeficiency virus seropositive and sernegative hemophiliacs infused for 3.5 years with recombinant factor VIII","volume":"83","author":"Mannucci PM","year":"1994","journal-title":"Blood"},{"key":"e_1_2_7_68_2","first-page":"132","article-title":"Effect of HIV\u20101 infection on CD4 cells in a hemophilia cohort","volume":"75","author":"Green D","year":"1990","journal-title":"Haematologica"},{"key":"e_1_2_7_69_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)90943-B"},{"key":"e_1_2_7_70_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1648841"},{"key":"e_1_2_7_71_2","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1055\/s-0038-1646430","article-title":"CD4 cells in HIV\u20101 infected haemophiliacs: effect of factor VIII concentrates","volume":"66","author":"Goldsmith JM","year":"1991","journal-title":"Thromb Haemostas"},{"key":"e_1_2_7_72_2","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1182\/blood.V78.8.1919.1919","article-title":"The impact of a very high purity factor VIII concentrate on the immune system of human immunodeficiency virus\u2010infected hemophiliacs: a randomized, prospective, two\u2010year comparison with an intermediate purity product","volume":"78","author":"Di Biasi R","year":"1991","journal-title":"Blood"},{"key":"e_1_2_7_73_2","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1182\/blood.V79.10.2800.bloodjournal79102800","article-title":"Purity of factor VIII concentrates and immune function in hemophiliacs","volume":"79","author":"Farrugia A","year":"1992","journal-title":"Blood"},{"key":"e_1_2_7_74_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)91706-R"},{"key":"e_1_2_7_75_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)92721-9"},{"key":"e_1_2_7_76_2","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1055\/s-0038-1642717","article-title":"Effects of factor VIII concentrates on the immune system of patients with hemophilia","volume":"74","author":"Mannucci PM","year":"1995","journal-title":"Thromb Haemostas"},{"key":"e_1_2_7_77_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1648871"},{"key":"e_1_2_7_78_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1651602"},{"key":"e_1_2_7_79_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1991.tb08055.x"},{"key":"e_1_2_7_80_2","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1182\/blood.V84.5.1666.1666","article-title":"Effect of low\u2010 and intermediate\u2010purity clotting factor therapy on progression of human immunodeficiency virus infection in congenital clotting disorders","volume":"84","author":"Gjerset GF","year":"1994","journal-title":"Blood"},{"key":"e_1_2_7_81_2","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1182\/blood.V82.4.1351.1351","article-title":"Effect on lymphocyte subsets of clotting factor therapy in human immunodeficiency virus\u20101\u2010negative congenital clotting disorders. The Transfusion Safety Study Group","volume":"82","author":"Hassett J","year":"1993","journal-title":"Blood"},{"key":"e_1_2_7_82_2","first-page":"25","article-title":"Factor VIII concentrates in HIV\u20101\u2010positive hemophiliacs \u2013 is pure better?","volume":"22","author":"Eichinger S","year":"1992","journal-title":"Haemostasis"},{"key":"e_1_2_7_83_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1648438"},{"key":"e_1_2_7_84_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)92345-0"},{"key":"e_1_2_7_85_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199602153340703"},{"key":"e_1_2_7_86_2","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1001\/jama.1996.03540020027025","article-title":"Serum HIV\u20101 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study","volume":"276","author":"O\u2019Brien TR","journal-title":"JAMA"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2516.1998.00172.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2516.1998.00172.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2516.1998.00172.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T11:44:01Z","timestamp":1694432641000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2516.1998.00172.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,9]]},"references-count":85,"journal-issue":{"issue":"5","published-print":{"date-parts":[[1998,9]]}},"alternative-id":["10.1046\/j.1365-2516.1998.00172.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2516.1998.00172.x","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,9]]}}}